Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous dendritic cell immunotherapy in mesothelioma
NL-OMON22849Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2006
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous tumor lysate-pulsed dendritic cells in mesothelioma, sponsored by Erasmus MC. Primary endpoints: Safety and Tolerability. Started Jan 2006; status: recruiting.
02
Drugs
autologous tumor lysate-pulsed dendritic cells
03
Conditions
mesothelioma
Beyond the preview
Go deeper on NL-OMON22849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON22849.